TriSalus Life Sciences (NASDAQ:TLSI) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Key Points

• TriSalus Life Sciences reported a quarterly loss of ($0.27) EPS, missing the consensus estimate by ($0.05).
• The stock's performance saw a slight increase, trading at $3.65, with a market cap of $138.12 million.
• Insider Richard Marshak sold 6,597 shares of the company, leading to an 8.71% decrease in his ownership stake.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.05), Zacks reports. TriSalus Life Sciences updated its FY 2025 guidance to EPS.

TriSalus Life Sciences Stock Performance

Shares of TLSI traded up $0.08 during midday trading on Tuesday, hitting $3.65. 77,406 shares of the stock were exchanged, compared to its average volume of 60,805. The firm has a market cap of $138.12 million, a P/E ratio of -3.26 and a beta of 0.48. The stock has a fifty day simple moving average of $4.88 and a 200 day simple moving average of $5.24. TriSalus Life Sciences has a 52-week low of $3.42 and a 52-week high of $6.04.

Insider Transactions at TriSalus Life Sciences

In related news, insider Richard Marshak sold 6,597 shares of TriSalus Life Sciences stock in a transaction on Monday, May 19th. The stock was sold at an average price of $5.18, for a total value of $34,172.46. Following the completion of the transaction, the insider directly owned 69,101 shares in the company, valued at approximately $357,943.18. This trade represents a 8.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 16,125 shares of company stock valued at $83,528 in the last ninety days. Company insiders own 27.50% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its holdings in TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company's stock valued at $41,000 after purchasing an additional 7,519 shares during the period. Geode Capital Management LLC boosted its holdings in TriSalus Life Sciences by 107.4% in the second quarter. Geode Capital Management LLC now owns 455,051 shares of the company's stock valued at $2,480,000 after purchasing an additional 235,627 shares during the period. Finally, Goldman Sachs Group Inc. purchased a new position in TriSalus Life Sciences in the first quarter valued at $187,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.